Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Craxi

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Journal of Hepatology|August 19, 2020
EASL Recognition Awardee 2020: Prof. Giovanna FattovichAntonio Craxi
Gut|July 15, 2017
Can we prevent and modify cardiometabolic disorders by controlling HCV infection?Salvatore Petta, Antonio Craxi
Best Practice & Research. Clinical Gastroenterology|December 4, 2012
Preface. Hepatitis C infectionHarry Janssen, Antonio Craxi
Seminars in Liver Disease|August 23, 2003
Clinical trial results of peginterferons in combination with ribavirinAntonio Craxi, Anna Licata
Journal of Hepatology|October 16, 2012
Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients"Salvatore Petta, Antonio Craxi
Antiviral Research|November 26, 2003
Pegylated interferons for chronic hepatitis BAntonio Craxi, W Graham Cooksley
Hepatology (Baltimore, Md.)|March 5, 2024
Hepatitis C elimination: Tailoring the approach to each country's needs and realitiesLoreta A Kondili, Antonio Craxi
Journal of Hepatology|August 24, 2014
HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?Tarik Asselah, Savino Bruno, Antonio Craxi
Journal of Hepatology|April 30, 2023
Hospital HCV elimination in addition to universal precautions could reduce incidence and infection burden in ItalyLoreta A Kondili, Maria Grazia Rumi, Antonio Craxi
Antiviral Therapy|November 1, 2012
HCV genotype 5: an orphan virusNabil Antaki, Dirar Abboud, Fadi Antaki, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Journal of Hepatology|August 19, 2020
EASL Recognition Awardee 2020: Prof. Giovanna FattovichAntonio Craxi
Gut|July 15, 2017
Can we prevent and modify cardiometabolic disorders by controlling HCV infection?Salvatore Petta, Antonio Craxi
Best Practice & Research. Clinical Gastroenterology|December 4, 2012
Preface. Hepatitis C infectionHarry Janssen, Antonio Craxi
Seminars in Liver Disease|August 23, 2003
Clinical trial results of peginterferons in combination with ribavirinAntonio Craxi, Anna Licata
Journal of Hepatology|October 16, 2012
Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients"Salvatore Petta, Antonio Craxi
Antiviral Research|November 26, 2003
Pegylated interferons for chronic hepatitis BAntonio Craxi, W Graham Cooksley
Hepatology (Baltimore, Md.)|March 5, 2024
Hepatitis C elimination: Tailoring the approach to each country's needs and realitiesLoreta A Kondili, Antonio Craxi
Journal of Hepatology|August 24, 2014
HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?Tarik Asselah, Savino Bruno, Antonio Craxi
Journal of Hepatology|April 30, 2023
Hospital HCV elimination in addition to universal precautions could reduce incidence and infection burden in ItalyLoreta A Kondili, Maria Grazia Rumi, Antonio Craxi
Antiviral Therapy|November 1, 2012
HCV genotype 5: an orphan virusNabil Antaki, Dirar Abboud, Fadi Antaki, et al.
Pageof 6